Maynard Um
-
-
-
-
-
-
-
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Tr
-
-
-
-
-
-
-
Tharimmune (THAR) Announces Key Leadership Appointments
-
-
-
-
-
-
-
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
-
-
-
-
-
-
-
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
-
-
-
-
-
-
-
Tharimmune (THAR) Announces 961K Share Offering at $2.10/sh
-
-
-
-
-
-
-
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
-
-
-
-
-
-
-
Tharimmune (THAR) to Merge With Intract Pharma
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

